Li Feng, Yi Ping, Pi Jingnan, Li Lanfang, Hui Jingyi, Wang Fang, Liang Aihua, Yu Jia
Institute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan, PR China.
Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, PR China.
Oncotarget. 2016 May 31;7(22):32821-34. doi: 10.18632/oncotarget.8739.
Alternative pre-mRNA splicing is a key mechanism for increasing proteomic diversity and modulating gene expression. Emerging evidence indicated that the splicing program is frequently dysregulated during tumorigenesis. Cancer cells produce protein isoforms that can promote growth and survival. The RNA-binding protein QKI5 is a critical regulator of alternative splicing in expanding lists of primary human tumors and tumor cell lines. However, its biological role and regulatory mechanism are poorly defined in gastric cancer (GC) development and progression. In this study, we demonstrated that the downregulation of QKI5 was associated with pTNM stage and pM state of GC patients. Re-introduction of QKI5 could inhibit GC cell proliferation, migration, and invasion in vitro and in vivo, which might be due to the altered splicing pattern of macroH2A1 pre-mRNA, leading to the accumulation of macroH2A1.1 isoform. Furthermore, QKI5 could inhibit cyclin L1 expression via promoting macroH2A1.1 production. Thus, this study identified a novel regulatory axis involved in gastric tumorigenesis and provided a new strategy for GC therapy.
可变前体mRNA剪接是增加蛋白质组多样性和调节基因表达的关键机制。新出现的证据表明,剪接程序在肿瘤发生过程中经常失调。癌细胞产生的蛋白质异构体可促进生长和存活。RNA结合蛋白QKI5是越来越多原发性人类肿瘤和肿瘤细胞系中可变剪接的关键调节因子。然而,其在胃癌(GC)发生发展中的生物学作用和调控机制尚不清楚。在本研究中,我们证明QKI5的下调与GC患者的pTNM分期和pM状态相关。重新引入QKI5可在体外和体内抑制GC细胞的增殖、迁移和侵袭,这可能是由于macroH2A1前体mRNA剪接模式的改变,导致macroH2A1.1异构体的积累。此外,QKI5可通过促进macroH2A1.1的产生来抑制细胞周期蛋白L1的表达。因此,本研究确定了一条参与胃癌发生的新调控轴,并为GC治疗提供了新策略。